Bicara Therapeutics Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Bicara Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $2.33M, a 1627.41% increase year-over-year.
- Bicara Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.58M, a 231.66% increase year-over-year.
- Bicara Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $436.00K, a 119.10% increase year-over-year.
- Bicara Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $135.00K, a 89.73% decline year-over-year.
- Bicara Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $2.78M, a 67.47% increase from fiscal 2024.
- Bicara Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.66M, a 1283.33% increase from fiscal 2023.
- Bicara Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $120.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $2.33M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $1.58M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $2.78M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $436.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $135.00K 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $477.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $1.66M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $199.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $1.31M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $50.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $120.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $32.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $27.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $43.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |